Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Biosimilars
The Icelandic-Israeli pairing of Alvotech and Teva Pharmaceutical Industries have announced that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use. 17 April 2024
Pharmaceutical
US healthcare giant Johnson & Johnson has announced its financial results for the first quarter of 2024. 16 April 2024
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has teamed up with US tech platform company Komodo Health. 10 April 2024
Biotechnology
UCB's Bimzelx (bimekizumab-bkzx) has taken a step closer to a new US approval, with the regulator accepting a supplemental Biologics License Application in hidradenitis suppurativa (HS). 4 April 2024
Biotechnology
US clinical-stage biotech Obsidian Therapeutics has closed a significantly oversubscribed $160.5 million Series C financing. 4 April 2024
Biotechnology
Oruka Therapeutics, a US biotech focused on developing biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, has entered into a merger agreement with ARCA biopharma. 3 April 2024
Pharmaceutical
A new licensing deal has been agreed between American firm Incyte and Hong Kong-based China Medical System Holdings (CMS). 2 April 2024
Biotechnology
Switzerland-based Roivant Sciences and Priovant Therapeutics today announced positive results from the Phase II study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. 2 April 2024
Biotechnology
Swiss pure-play dermatology category leader Galderma Group today announced the pricing of its Initial Public Offering (IPO) at 53 Swiss francs per share, at the top of the announced price range.
The shares will 21 March 2024
Biotechnology
Germany’s Boehringer Ingelheim has announced that the US Food and Drug Administration has given a new approval to Spevigo (spesolimab-sbzo). 19 March 2024
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze